Abstract
We present the case of a male patient not vaccinated against hepatitis B virus (HBV) and with reactivity to a surface antibody who, after immunosuppression for a multiple myeloma, had HBV reactivation. Pharmacological HBV suppression was tried, but viremia could not be suppressed. Production-detection core mutations or immunity issues can explain this clinical phenomenon.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
MeSH terms
-
Antiviral Agents / therapeutic use
-
Guanine / analogs & derivatives
-
Guanine / therapeutic use
-
Hematopoietic Stem Cell Transplantation
-
Hepatitis B / diagnosis*
-
Hepatitis B / drug therapy
-
Hepatitis B / immunology
-
Hepatitis B Antibodies / blood*
-
Hepatitis B Antibodies / immunology
-
Hepatitis B Core Antigens / immunology*
-
Hepatitis B virus / immunology*
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / therapy
Substances
-
Antiviral Agents
-
Hepatitis B Antibodies
-
Hepatitis B Core Antigens
-
entecavir
-
Guanine